{
    "nctId": "NCT02431676",
    "briefTitle": "Survivorship Promotion In Reducing IGF-1 Trial",
    "officialTitle": "Trial of Behavioral Weight Loss and Metformin Treatment to Lower Insulin Growth Factor in Cancer Survivors",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma of Skin, Endometrial Cancer, Liver Cancer, Pancreatic Cancer, Rectal Cancer, Kidney Cancer, Other Solid Malignant Tumors",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 121,
    "primaryOutcomeMeasure": "IGF-1 Levels",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women and men ages 18 or older\n* Have been previously diagnosed with a malignant solid tumor, completed their required surgical, and/or chemotherapy and/or radiation curative intent therapy at least three months prior to enrollment, and have an anticipated treatment-free life span of 12 months or longer. Chemoprophylaxis with tamoxifen or aromatase inhibitors for breast cancer in women and anti- Luteinizing hormone-releasing hormone (LHRH) therapy for prostate cancer in men will be permitted.\n* Have a BMI of 25 kg/m\\^2 or greater and weight \\<=400 lbs.\n* Willingness to accept randomization to each of the three arms\n* Willingness to change diet, physical activity, and weight\n* Regular access to computer with a reliable Internet connection\n* Ability to send and receive emails\n* Ability to complete online forms\n* Access to phone\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Women who are breastfeeding, pregnant, or planning pregnancy within the next year\n* Medication-treated diabetes\n* Fasting blood glucose \\>=200 mg/dL, or fasting blood glucose \\>=126 and \\<200 mg/dL and HbA1C \\>=7%\n* Current or prior regular use of metformin within the past 3 months\n* Uncontrolled concurrent medical condition likely to limit compliance with the study interventions\n* Received any chemotherapy (unless anti-hormonal therapy) and/or radiation three months or less prior to the proposed intervention date\n* Have a prior history of lactic acidosis by self-report\n* Prior or planned bariatric surgery\n* Have significant renal disease or dysfunction defined as Estimated glomerular filtration rate (eGFR)\\<45\n* Have significant hepatic dysfunction \\[Aspartate aminotransferase (AST)/Alanine transaminase (ALT) \u2265 2 x upper limit of normal (ULN) or reported liver disease\\]\n* Self-reported average consumption of \\> 14 alcoholic drink per week\n* Currently enrolled or planned to enroll in weight loss program\n* Hemoglobin \\<9 g/dl\n* Platelet count \\<100\n* White blood cell count (WBC) \\<2.5\n* Plans to relocate from the area within one years\n* Use of prescription weight loss medication(s) (e.g., lorcaserin, topiramate/phentermine, phentermine, liraglutide, and bupropion/naltrexone), including off label use of drugs for weight loss or over-the-counter weigh loss medications such as Orlistat within the past 6 months.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}